<DOC>
	<DOCNO>NCT00739687</DOCNO>
	<brief_summary>Several line evidence suggest Advanced Glycation End-products ( AGEs ) play role development progression heart failure . The AGE-crosslink breaker Alagebrium improve cardiac function symptom experimental preclinical small human heart failure study . These result yet confirm randomize control clinical trial . Objective : evaluate safety efficacy alagebrium subject diagnose heart failure . This randomized , double-blind , placebo-controlled trial ass effect 400 mg ( 2 x 100 mg bid ) alagebrium versus placebo 9 month . 100 subject study ( 50 per treatment group ) approximately 6 center . Procedures : exercise testing ( VO2 max ; primary variable ) , ECGs blood sampling .</brief_summary>
	<brief_title>Safety &amp; Efficacy ALT-711 ( Alagebrium ) Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>NYHA IIIV heart failure Echocardiographic ejection fraction ≤ 45 % ( echo need repeat screen visit prior echo record indicate ejection fraction &lt; 40 % ) Duration heart failure &gt; 3 month Stable heart failure medical therapy &gt; 1 month Patients need able understand content willing provide inform consent Patient ≤ 18 year History myocardial infarction previous 6 month History stroke/TIA/RIND previous 6 month Severe valvular dysfunction Severe pulmonary disease History systemic inflammatory collagen vascular disease Active treat malignancy within 12 month prior inclusion Any significant condition either medical nonmedical could lead difficulty comply protocol Patients cardiac resynchronisation therapy ( CRT ) schedule CRT implantation Pacemaker therapy ( unless rescue pace ≤ 40 bpm ) schedule pacemaker implantation History valve replacement surgery Uncontrolled diabetes mellitus ( HbA1c &gt; 9.5 % ) Clinically significant renal disturbance ( sMDRD calculate GFR≤30 mL/min/1.73m2 ; sMDRD calculate 186 x serum Cr ( mg/dl ) 1.154 x years0.203 x ( 0.742 female ) x ( 1.210 African American ) Clinically significant liver disease ( ASAT/ALAT &gt; 2,5 time upper limit normal ) Severe anemia baseline ( Hemoglobin &lt; 10 g/dl &lt; 6.2 mmol/l ) Use investigational drug ( ) within 30 day prior screen Pregnancy active breastfeeding ( urine pregnancy test perform female subject childbearing potential ) * Active pericarditis/myocarditis The inability patient undergo exercise testing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Chronic Heart Failure</keyword>
</DOC>